It protects against 15 serotypes. PCV20, also known as Prevnar 20, was licensed in 2021 for adults 18 years and older, then in 2023 was recommended for ages 6 weeks and up. It covers 20 serotypes.

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

Spread of multidrug resistance in non-PCV13/PCV20 serotypes of Streptococcus pneumoniae: A cross-sectional study ten years after the introduction of pneumococcal conjugate vaccine in Japan.

Merck receives positive EU CHMP opinion for Capvaxive for pneumococcal vaccination in adults: Rahway, New Jersey Monday, February 3, 2025, 12:00 Hrs [IST] Merck, known as MSD outs ...

Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal ...

Capvaxive targets serotypes that account for approximately ... which evaluated Capvaxive compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults aged 18 years and above who had ...

Pneumococcal 20-valent conjugate vaccine (diphtheria CRM197 protein); contains a total of 46.2mcg saccharides per 0.5mL; susp for IM inj; contains aluminum. After shipping, Prevnar 20 may arrive ...